VeloGene - TurboMice™
45 Days from Cell to Mice
Homozygous Mice · 4Rs Ethical Framework · Large & Complex Knockins · Rapid Model Generation

VeloGene Biotechnology is a trusted international biotech trade partner, fully-owned subsidiary of MingCeler Biotech, delivering comprehensive mouse model solutions—including custom gene edited mouse and gene engineering mouse variants—for multinational pharmaceutical firms, biotech startups and global research labs across North America, Europe and South Korea. Supported by parent MingCeler Biotech’s game-changing tetraploid complementation TurboMice™ technology, we supply genetically consistent homozygous mouse strains within just 2 to 5 months. Our technology avoids slow traditional chimera breeding cycles, drastically shortening model preparation periods to advance global rare disease, oncology and gene therapy preclinical research.
What is TurboMice™?
TurboMice™ is the industry's most cutting-edge rapid model generation technology worldwide, designed to revolutionize the production of genetically engineered mice. Pioneered by Dr. Wu Guangming, this proprietary platform is powered by advanced Tetraploid Complementation Technology (TCT) and precision stem cell editing. Unlike traditional CRISPR-mediated platforms that suffer from breeding delays and off-target risks, TurboMice™ completely eliminates the chimeric phase, delivering fully homozygous mice with excellent genetic consistency.
Rather than relying on multi-generational breeding after genomic modification, VeloGene employs Tetraploid Complementation Technology (TCT) to drive the direct development of edited Embryonic Stem Cells (ESCs) into complete, live animal cohorts. By eliminating breeding-related bottlenecks, we radically compress standard in vivo readiness timelines to just 3–5 months, achieving a 45-day turnaround from cell line validation to functional mice. VeloGene provides premium, SPF-grade genetically engineered mouse models, specialized services, and end-to-end technical support to elite academic institutions, research centers, and biopharmaceutical enterprises globally.





